Cargando…

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management

BACKGROUND: After each cycle of [(177)Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs. Absorbed doses are routinely calculated from three quantitative single-photon emission com...

Descripción completa

Detalles Bibliográficos
Autores principales: Chicheportiche, Alexandre, Ben-Haim, Simona, Grozinsky-Glasberg, Simona, Oleinikov, Kira, Meirovitz, Amichay, Gross, David J., Godefroy, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977807/
https://www.ncbi.nlm.nih.gov/pubmed/31975156
http://dx.doi.org/10.1186/s40658-020-0273-8
_version_ 1783490591021072384
author Chicheportiche, Alexandre
Ben-Haim, Simona
Grozinsky-Glasberg, Simona
Oleinikov, Kira
Meirovitz, Amichay
Gross, David J.
Godefroy, Jeremy
author_facet Chicheportiche, Alexandre
Ben-Haim, Simona
Grozinsky-Glasberg, Simona
Oleinikov, Kira
Meirovitz, Amichay
Gross, David J.
Godefroy, Jeremy
author_sort Chicheportiche, Alexandre
collection PubMed
description BACKGROUND: After each cycle of [(177)Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs. Absorbed doses are routinely calculated from three quantitative single-photon emission computed tomography (SPECT) studies corrected by computed tomography (CT) acquired at t(1) = 24 h, t(2) = 96 h, and t(3) = 168 h after the first cycle of treatment. After following cycles, a single SPECT/CT study is performed. The aim of the present study is to assess the feasibility of a “two time point” quantitative SPECT/CT protocol after the first PRRT cycle and its impact on patient management. Quantitative SPECT/CT data of 25 consecutive patients with metastatic neuroendocrine tumors after PRRT were retrospectively analyzed. Radiation-absorbed doses calculated using the standard protocol with three SPECT/CT studies acquired at (t(1), t(2), t(3)) were compared to those obtained from three different “two time point” protocols with SPECT/CT studies performed at (t(1), t(2)), (t(1), t(3)), or (t(2), t(3)). RESULTS: The best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t(1), t(3)) protocol with mean relative differences of − 1.0% ± 2.4%, 0.4% ± 3.1%, − 0.9% ± 4.0%, − 0.8% ± 1.1%, and − 0.5% ± 2.0%, respectively, and correlation coefficients of r = 0.99 for all. In all patients, there was no difference in the management decision of whether or not to stop PRRT because of unsafe absorbed dose to risk organs using either the standard protocol or the (t(1), t(3)) protocol. CONCLUSION: These preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time.
format Online
Article
Text
id pubmed-6977807
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-69778072020-02-06 Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management Chicheportiche, Alexandre Ben-Haim, Simona Grozinsky-Glasberg, Simona Oleinikov, Kira Meirovitz, Amichay Gross, David J. Godefroy, Jeremy EJNMMI Phys Original Research BACKGROUND: After each cycle of [(177)Lu]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs. Absorbed doses are routinely calculated from three quantitative single-photon emission computed tomography (SPECT) studies corrected by computed tomography (CT) acquired at t(1) = 24 h, t(2) = 96 h, and t(3) = 168 h after the first cycle of treatment. After following cycles, a single SPECT/CT study is performed. The aim of the present study is to assess the feasibility of a “two time point” quantitative SPECT/CT protocol after the first PRRT cycle and its impact on patient management. Quantitative SPECT/CT data of 25 consecutive patients with metastatic neuroendocrine tumors after PRRT were retrospectively analyzed. Radiation-absorbed doses calculated using the standard protocol with three SPECT/CT studies acquired at (t(1), t(2), t(3)) were compared to those obtained from three different “two time point” protocols with SPECT/CT studies performed at (t(1), t(2)), (t(1), t(3)), or (t(2), t(3)). RESULTS: The best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t(1), t(3)) protocol with mean relative differences of − 1.0% ± 2.4%, 0.4% ± 3.1%, − 0.9% ± 4.0%, − 0.8% ± 1.1%, and − 0.5% ± 2.0%, respectively, and correlation coefficients of r = 0.99 for all. In all patients, there was no difference in the management decision of whether or not to stop PRRT because of unsafe absorbed dose to risk organs using either the standard protocol or the (t(1), t(3)) protocol. CONCLUSION: These preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time. Springer International Publishing 2020-01-23 /pmc/articles/PMC6977807/ /pubmed/31975156 http://dx.doi.org/10.1186/s40658-020-0273-8 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Chicheportiche, Alexandre
Ben-Haim, Simona
Grozinsky-Glasberg, Simona
Oleinikov, Kira
Meirovitz, Amichay
Gross, David J.
Godefroy, Jeremy
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title_full Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title_fullStr Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title_full_unstemmed Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title_short Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
title_sort dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977807/
https://www.ncbi.nlm.nih.gov/pubmed/31975156
http://dx.doi.org/10.1186/s40658-020-0273-8
work_keys_str_mv AT chicheportichealexandre dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT benhaimsimona dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT grozinskyglasbergsimona dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT oleinikovkira dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT meirovitzamichay dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT grossdavidj dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement
AT godefroyjeremy dosimetryafterpeptidereceptorradionuclidetherapyimpactofreducednumberofposttreatmentstudiesonabsorbeddosecalculationandonpatientmanagement